A novel model of occlusive thrombus formation in mice.
A novel model to induce occlusive thrombus formation was developed in mice in vivo. Mice were simultaneously treated with ligation and cuff placement at the left carotid artery. At 7 days after the treatment, occlusive thrombus was observed at the intracuff region, but not in the distal and proximal regions of the cuff, and not induced by a single treatment of ligation or cuff placement. The plasma levels of von Willebrand factor (vWF), which represent the endothelial status, were significantly increased in combined treatment of ligation and cuff placement 1 day after the operation. Whereas no significant changes in plasma vWF were observed in either single treatment of ligation or cuff placement. The expression of vWF, considered to be the endothelial marker, was detected on the luminal surface distal and proximal to the cuff and the carotid artery in the single treatment groups treated with either ligation or cuff placement, but was not detected in the intracuff region. Furthermore, the binding of Griffolia Simplicifolia Lectin-I (GSL-I) and endothelial nitric oxide synthase (eNOS) expression indicating the endothelial integrity was not detected in the intracuff region. Intermittent injections of ancrod, which decreases the plasma fibrinogen, inhibited occlusive thrombus formation in the intracuff region. The expression of eNOS was detected at the distal and proximal but not the intracuff region of the carotid artery treated with ancrod. Daily administration of aspirin significantly suppressed the thrombus formation in this model. These results indicate that occlusive thrombus formation accompanied by endothelial damage or dysfunction is induced by the combined application of ligation and cuff placement at the carotid artery, and suggest that this endothelial damage or dysfunction may be one pathogenesis of thrombogenesis in this model.
Sasaki
Takeshi
T
Department of Geriatrics, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Kuzuya
Masafumi
M
Cheng
Xian-Wu
XW
Nakamura
Kae
K
Tamaya-Mori
Norika
N
Maeda
Keiko
K
Kanda
Shigeru
S
Koike
Teruhiko
T
Sato
Kohji
K
Iguchi
Akihisa
A
D000818:Animals; D001157:Arterial Occlusive Diseases / Q000097:blood / Q000188:drug therapy / Q000473:pathology*; D001241:Aspirin / Q000627:therapeutic use; D002340:Carotid Artery Diseases / Q000097:blood / Q000188:drug therapy / Q000473:pathology; D017536:Carotid Artery, Common / Q000473:pathology / Q000601:surgery; D004195:Disease Models, Animal; D004730:Endothelium, Vascular / Q000201:enzymology / Q000473:pathology; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D008026:Ligation; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D019001:Nitric Oxide Synthase / Q000378:metabolism; D052247:Nitric Oxide Synthase Type II; D052250:Nitric Oxide Synthase Type III; D013927:Thrombosis / Q000097:blood / Q000209:etiology / Q000473:pathology*; D014841:von Willebrand Factor / Q000032:analysis
D005343:Fibrinolytic Agents; D014841:von Willebrand Factor; D019001:Nitric Oxide Synthase; D052247:Nitric Oxide Synthase Type II; D052250:Nitric Oxide Synthase Type III; C496315:Nos3 protein, mouse; D001241:Aspirin